This randomised ( using a telephone or web-based randomisation system ) , parallel-group , controlled 26 week trial of 581 patients with type 2 diabetes mellitus on prior monotherapy ( HbA ( 1c ) 7.5-10 % ) and combination therapy ( 7.0-10 % ) was conducted in 107 centres in 17 countries .
